Several national and global scientific associations and organizations, including the World Health Organization (WHO), the American Urological Association (AUA), and the European Association of Urology (EAU) have offered many univariate and multivariate operational definitions for PE. However, several definitions are vague and unclear as they do not clearly describe the disorder. The table below enlists a few of the definitions about PE being followed in different regions/countries.

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 REPORT COVERAGE

5 REPORT ASSUMPTIONS & CAVEATS

6 MARKET AT A GLANCE

7 INTRODUCTION

8 ISSN GUIDELINES ON PREMATURE EJACULATION

9 CLINICAL TRIAL LANDSCAPE

10 PIPELINE LANDSCAPE

11 MARKET DYNAMICS

12 GLOBAL PREMATURE EJACULATION MARKET

13 BY DRUG CLASS

14 BY ROUTE OF ADMINISTRATION

15 BY GEOGRAPHY

15.1 MARKET OVERVIEW

16 NORTH AMERICA

16.1 MARKET OVERVIEW

16.2 MARKET SIZE & FORECAST

16.3 KEY COUNTRIES

16.4 US: MARKET SIZE & FORECAST

16.4.1 SEGMENTATION BY DRUG CLASS

16.4.2 SSRIS: MARKET SIZE & FORECAST

16.4.3 PDE5 INHIBITORS: MARKET SIZE & FORECAST

16.4.4 ANESTHETIC AGENTS: MARKET SIZE & FORECAST

16.5 CANADA: MARKET SIZE & FORECAST

16.5.1 SEGMENTATION BY DRUG CLASS

16.5.2 SSRIS: MARKET SIZE & FORECAST

16.5.3 PDE5 INHIBITORS: MARKET SIZE & FORECAST

16.5.4 ANESTHETIC AGENTS: MARKET SIZE & FORECAST

16.6 KEY TREND, ENABLERS, AND RESTRAINTS

17 EUROPE

18 APAC

19 LATIN AMERICA

20 MIDDLE-EAST & AFRICA

21 COMPETITIVE LANDSCAPE

22 KEY COMPANY PROFILES

23 OTHER PROMINENT VENDORS

24 REPORT SUMMARY

25 APPENDIX